EARLY NEPHROPATHY STUDY IN DIABETES (END-IT)

$38,810U54FY2009RRNIH

Charles R. Drew University Of Med & Sci, Los Angeles CA

Investigators

Linked publications & trials

Paper 24073333 Paper 22561025 Paper 21550951 Paper 21278812 Paper 21146881 Paper 20873952 Paper 20803415 Paper 20675947 Paper 20657753 Paper 20629245 Paper 20629242 Paper 20629240 Paper 20144693 Paper 20077598 Paper 20073296 Paper 20061043 Paper 19903933 Paper 19806842 Paper 19729522 Paper 19696220 Paper 19657329 Paper 19537345 Paper 19480090 Paper 19300090 Paper 19244563 Paper 19171736 Paper 19110905 Paper 18987917 Paper 18826856 Paper 18820230 Paper 18819057 Paper 18771713 Paper 18646341 Paper 18646340 Paper 18640483 Paper 18525000 Paper 18524870 Paper 18523930 Paper 18507210 Paper 18434712 Paper 18417740 Paper 18385428 Paper 18359412 Paper 18229777 Paper 18221393 Paper 17985510 Paper 17804675 Paper 17598314 Paper 17578763 Paper 17563338 Paper 17563024 Paper 17386339 Paper 17259485 Paper 17235523 Paper 17065692 Paper 17064351 Paper 17027569 Paper 16926379 Paper 16919545 Paper 16919355 Paper 16915537 Paper 16873540 Paper 16732030 Paper 16681136 Paper 16681135 Paper 16681130 Paper 16681127 Paper 16681125 Paper 16610924 Paper 16328569 Paper 16315388 Paper 16315387 Paper 16315379 Paper 16263817 Paper 16173323 Paper 15994347 Paper 15956344 Paper 15920088 Paper 15761661 Paper 15719874 Paper 15712785 Paper 15616008 Paper 15585599 Paper 15472231 Paper 15291740 Paper 15253322 Paper 15186526 Paper 15030297 Paper 14995078 Paper 14984002 Paper 14764787 Paper 14640013 Paper 12960001 Paper 12824080 Paper 12765951 Paper 12721153 Paper 12670837 Paper 12667812 Paper 12643111 Paper 12616185

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A. SPECIFIC AIMS This hypothesis will be tested through the following specific aims: 1. Assess the effect of standard-versus-aggressive RAAS inhibition on progression of atherosclerotic disease on a primary outcome of structural vascular changes as assessed by carotid intima media thickness, 2. Assess the effect of standard-versus-aggressive RAAS inhibition on progression of atherosclerotic disease on a secondary outcome of functional vascular changes as assessed by finger plethysmography, and 3. Examine the relationship of vascular changes to both baseline and change in urinary protein excretion rates.

View original record on NIH RePORTER →